GLP-1, a gut hormone: weight, blood sugar, and safety
Tirzepatide may curb hunger before weight falls
Large final studies, called phase 3, measured weight, blood sugar, and harm. A source number follows each finding.
The weekly shot links hunger, blood sugar, and weight
Hunger may fade before the belt feels loose. People often feel full sooner. Tirzepatide is a prescription drug. One shot is given each week. After a meal, the gut releases two hormones that the drug copies. GLP-1 is the fullness hormone. Its job keeps food in the stomach longer. GLP-1 also tells the brain that enough food has arrived. The insulin-helping hormone asks the pancreas for more insulin when sugar rises. The drug copies both hormone jobs.
The FDA cleared Tirzepatide in May 2022 for type 2 diabetes. November 2023 added weight care to the approved uses. SURMOUNT-1 studied 2,539 people. At 15 mg, average weight changed -20.9% over 72 weeks. People on placebo received no Tirzepatide. Average change there was -3.1% [4]. A later study compared two approved shots. Average change was -20.2% with Tirzepatide and -13.7% with a drug that copies GLP-1 alone [5].
You may lose more weight or less weight. The Tirzepatide effects page covers nausea, muscle loss, and personal reports.
The weight studies found large average losses
SURMOUNT-1 tracked 2,539 people for 72 weeks. Average weight changed -15.0%, -19.5%, and -20.9%. The weekly amounts were 5, 10, and 15 mg. The placebo group changed -3.1% [4]. At 15 mg, 57% lost at least 20% of their weight. Loss that large had once appeared mainly after weight-loss surgery.
SURMOUNT-3 started after a 12-week food and exercise plan. Its 579 people entered after losing at least 5%. During the next 72 weeks, average change with Tirzepatide was -18.4%. The placebo group gained +2.5%. The gap was -20.8 percentage points [10].
SURMOUNT-5 followed 751 people for 72 weeks. Each dose rose only while side effects stayed bearable. Average change was -20.2% with Tirzepatide. The other drug, which copies GLP-1 alone, brought -13.7% [5]. Study math made a fluke unlikely. More people on Tirzepatide reached 10%, 15%, 20%, and 25% loss.
Every figure blends all the people studied. Your scale may differ. The Tirzepatide research page has more study notes.
Tirzepatide approval covers diabetes, weight, and sleep
In May 2022, the first FDA approval covered adults with type 2 diabetes. Food and exercise were also part of care [9]. November 2023 brought long-term weight care. Doctors call the entry measure body mass index. It puts height and weight into one score. A doctor can work out your score from those two measures. A score of 30 kilograms per square meter or more can count. So can 27 kilograms per square meter with a weight-linked health problem [9]. A later approval covered serious sleep apnea with obesity [9]. Sleep apnea causes many short pauses in breathing overnight.
Five large final SURPASS studies, called phase 3, covered type 2 diabetes. This last test stage uses large groups. SURPASS-2 compared Tirzepatide with a shot that copies GLP-1 alone. It followed 1,879 people for 40 weeks. The weekly amounts were 5, 10, or 15 mg. A blood test looked back at several months of sugar. Tirzepatide lowered that test by 2.01, 2.24, and 2.30 percentage points. Semaglutide lowered it 1.86 points [3]. Those aren’t points on a home sugar meter. Tirzepatide produced the larger drop at every amount.
A prescription is required. The approval leaves out type 1 diabetes. Full papers appear under Tirzepatide references.
FDA approval can’t choose for you. Bring the label to a doctor familiar with your health.
Tirzepatide stays in the blood all week
Linked protein parts make up Tirzepatide. Changes to the chain let it take on both hormone jobs. A fatty side part lets the drug travel with albumin, a common blood protein. This slows the drug’s exit. About five days pass before half leaves [1][7]. This slow exit lets a shot cover the week.
A study measured how long Tirzepatide stayed in people’s blood. People of many body sizes had much the same weekly timing [7].
GLP-1 is the hormone that slows the stomach. A dish test on cells compared Tirzepatide’s GLP-1 action with the insulin-helping hormone. Tirzepatide acted more strongly through the insulin-helping hormone. Cells in a dish don’t reveal how someone will feel [2].
Only a shot placed under the skin has approval. What is Tirzepatide explains the body changes.
Weekly timing can’t predict your response.
Tirzepatide results differed from study to study
The main Tirzepatide results came from careful comparisons. A draw placed each person into a study group. Some received placebo, which contained no Tirzepatide. Others got an approved drug. This makes the weight and blood sugar findings easier to trust.
SURMOUNT-1 found -20.9% average weight change at 15 mg. It tracked 2,539 people for 72 weeks [4]. SURMOUNT-3 found -18.4% after a food and exercise plan. Its 579 people were tracked for 72 weeks [10]. SURMOUNT-5 followed 751 people for 72 weeks. Average change was -20.2% with Tirzepatide and -13.7% with semaglutide [5]. SURPASS-2 covered type 2 diabetes for 40 weeks. At 15 mg, the test that looks back over months fell -2.30 points. Semaglutide brought -1.86 points among 1,879 people [3]. These points aren’t home meter readings.
SURMOUNT-OSA found fewer breathing stops during sleep. The adults had serious sleep apnea and obesity [12]. Other studies looked at heart failure and liver disease.
Stopping changed the weight result. SURMOUNT-4 moved some people to placebo. Their weight returned. Those who stayed on Tirzepatide lost more [13]. A later SURMOUNT-4 report found worse blood sugar and heart risk signs as weight returned [14].
Group findings can’t name the result you’ll see.